Skip to content
2000
Volume 13, Issue 1
  • ISSN: 1570-1611
  • E-ISSN: 1875-6212

Abstract

Hypertension (HTN) and chronic kidney disease (CKD) often coexist sharing common pathophysiological factors that both in combination and separately induce fibrotic changes in the heart provoking atrial fibrillation (AF). AF, per se, is associated with a 4- to 5-fold increased risk of stroke and a 2-fold increased risk of all-cause death. The co-existence of AF with HTN and renal dysfunction considerably increases morbidity and mortality. Management of AF in hypertensive patients with CKD is complex and multidisciplinary, since these patients have both a prothrombotic state and a coagulopathy with an increased tendency for bleeding. Novel oral anticoagulants such as dabigatran, rivaroxaban and apixaban offer better efficacy and safety especially in patients without optimal treatment with vitamin K antagonists.

Loading

Article metrics loading...

/content/journals/cvp/10.2174/1570161112666140519154615
2015-01-01
2025-05-29
Loading full text...

Full text loading...

/content/journals/cvp/10.2174/1570161112666140519154615
Loading

  • Article Type:
    Research Article
Keyword(s): anticoagulants; Atrial fibrillation; chronic kidney disease; hypertension
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test